About Drugs in Context

Drugs in Context is an open access, peer-reviewed, continuous publication of international standing. It is a member of the Directory of Open Access Journals (https://doaj.org/). It is listed on PubMed and all articles are free-to-view/download immediately on PubMed Central.

Metrics: SJR/Scimago: Q1 title; H index = 10; SJR = 1.193. Equivalent Impact Factor = 3.07.

Articles: we publish high-quality, peer-reviewed original research papers and topical review articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. Other article types are considered.

Peer review: we conduct single-blind external peer review on all manuscripts with comments from at least two peer reviewers. Our aim is to obtain a first editorial decision within 3 weeks of manuscript submission and online publication within 3 weeks of acceptance.

Submit your article: check the 'AUTHORS' pages for full information.

Latest Article

Brodalumab in psoriasis: evidence to date and clinical potential

Amy C Foulkes BMedSci (Hons), BMBS, MRCP (Derm), PhD, Richard B Warren BSc (Hons), MBChB (Hons), MRCP, PhD

Articles 2014

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents

Eva M Vivian

The cost of biologics for psoriasis is increasing

Judy Cheng, Steven R Feldman

One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA

Susan T Arthur, Joshua M Noone, Bryce A Van Doren, Debosoree Roy, Christopher M Blanchette

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Joshua J Neumiller

Study protocol for a randomized, controlled trial comparing the efficacy of two educational interventions to improve inhalation techniques in patients with chronic obstructive pulmonary disease (COPD): TIEPOC Study.

José Leiva-Fernández, Francisca Leiva-Fernández, Rubén L Vázquez-Alarcón, Antonio García-Ruiz, Daniel Prados-Torres, Pilar Barnestein-Fonseca